Interaction between Hyperhomocysteinemia and Inherited Thrombophilic Factors in Venous Thromboembolism

ABSTRACT

Hyperhomocysteinemia is an established risk factor for deep vein thrombosis. Factor V Leiden has been reported to potentiate the thrombotic risk related with severe hyperhomocysteinemia, being more represented in thrombotic patients with homocystinuria as compared with patients without a history of thrombosis. The results concerning the interaction between moderate hyperhomocysteinemia and inherited thrombophilic factors such as Factor V Leiden or the prothrombin G20210A mutation are contradictory. The relative risk for venous thrombosis has been reported to be increased 10- to 50-fold in patients carrying both hyperhomocysteinemia and inherited thrombophilia in comparison with normal controls, suggesting a synergistic interaction, yet other studies failed to confirm such conclusion. The heterogeneity of these findings is in part due to the small number of individuals with double defects, leading to statistically unreliable results. Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism. In fact, in most of the studies the presence of the C677T MTHFR homozygous genotype does not increase the thrombotic risk associated with Factor V Leiden or the prothrombin mutation.

Hyperhomocysteinemia - venous thrombosis - inherited thrombophilia - Factor V Leiden - prothrombin G20210A mutation

REFERENCES

• 1 D'Angelo A, Selhub J. Homocysteine and thrombotic disease.  Blood . 1997;  90 1-11
• 2 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost . 1999;  81 165-176
• 3 Falcon C R, Cattaneo M, Panzeri D, Martinelli I, Mannucci P M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.  Arterioscler Thromb . 1994;  14 1080-1083
• 4 Fermo I, Viganò D'Angelo S, Paroni R. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.  Ann Intern Med . 1995;  123 747-753
• 5 Ridker P M, Hennekens C H, Selhub J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.  Circulation . 1997;  95 1777-1782
• 6 den Heijer M, Koster T, Blom H J. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med . 1996;  334 759-762
• 7 Simioni P, Prandoni P, Burlina A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study.  Thromb Haemost . 1996;  76 883-886
• 8 Eichinger S, Stumpflen A, Hirschl M. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism .  Thromb Haemost . 1998;  80 566-569
• 9 Gonzalez Y, Souto J C, Mateo J. Moderate hyperhomocysteinemia is a highly prevalent defect in Spanish patients with venous thromboembolic disease.  Haematologica . 1998;  83 1126-1127
• 10 den Heijer M, Blom H J, Gerrits W BJ. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis ?.  Lancet . 1995;  345 882-885
• 11 den Heijer M, Rosendaal F R, Blom H J, Gerrits W BJ, Bos G MJ. Hyperhomocysteinemia and venous thrombosis: A meta-analysis.  Thromb Haemost . 1998;  80 874-877
• 12 Arruda V R, von Zuben P M, Chiaparini L C, Annichino-Bizzacchi J M, Costa F F. The mutation Ala677Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis.  Thromb Haemost . 1997;  77 818-821
• 13 Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism.  Br J Haematol . 1997;  97 804-806
• 14 Salden A, Keeney S, Hay C RM, Cumming A M. The C677T MTHFR variant and the risk of venous thrombosis.  Br J Haematol . 1997;  99 472
• 15 Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: Interaction with factor V Leiden and prothrombin (F2G20210A) mutations.  Br J Haematol . 1998;  103 42-44
• 16 Kluijtmans L AJ, den Heijer M, Reitsma P H. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis.  Thromb Haemost . 1998;  79 254-258
• 17 De Stefano V, Chiusolo P, Paciaroni K. Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease.  Thromb Haemost . 1998;  79 686-687
• 18 Margaglione M, D'Andrea G, d'Addedda M. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the factor V Leiden and the prothrombin A^{2 0 2 1 0} mutation.  Thromb Haemost . 1998;  79 907-911
• 19 Alhenc-Gelas M, Arnaud E, Nicaud V. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes.  Thromb Haemost . 1999;  81 506-510
• 20 Cattaneo M, Chantarangkul V, Taioli E, Santos J H, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.  Thromb Res . 1999;  93 1-8
• 21 Cattaneo M, Tsai M Y, Bucciarelli P. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (Factor V:Q^{5 0 6}).  Arterioscler Thromb Vasc Biol . 1997;  17 1662-1666
• 22 Mandel H, Brenner B, Berant M. Coexistence of hereditary homocystinuria and factor V Leiden. Effect on thrombosis.  N Engl J Med . 1996;  334 763-768
• 23 Quéré I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene.  N Engl J Med . 1996;  335 289
• 24 Kluijtmans L AJ, Boers G HJ, Verbruggen B. Homozygous cystathionine β-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood . 1998;  91 2015-2018
• 25 Yap S, O'Donnell K A, O'Neill C. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine β-synthase deficiency.  Thromb Haemost . 1999;  81 502-505
• 26 D'Angelo A, Fermo I, Viganò D'Angelo S. Thrombophilia, homocystinuria, and mutation of the factor V gene.  N Engl J Med . 1996;  335 289
• 27 De Stefano V, Zappacosta B, Persichilli S. Prevalence of mild hyperhomocysteinemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease.  Br J Haematol . 1999;  106 564-568
• 28 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management .  Blood . 1996;  87 3531-3544
• 29 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
• 30 Rintelen C, Pabinger I, Lechner K. No evidence for an increase of the risk for venous thrombosis in patients with factor V Leiden by the homozygous mutation in the methylenetetrahydrofolate reductase gene.  Thromb Haemost . 1997;  569 (569)
• 31 De Stefano V, Chiusolo P, Paciaroni K. Prevalence of factor V 1691G to A and methylenetetrahydrofolate reductase 677C to T mutated genes in patients with venous thrombosis.  Thromb Haemost . 1997;  569 (569)
• 32 Tosetto A, Rodeghiero F, Martinelli I. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation.  Br J Haematol . 1998;  103 871-876